522 Shares in Axon Enterprise, Inc (NASDAQ:AXON) Bought by Kesler Norman & Wride LLC

Kesler Norman & Wride LLC acquired a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 522 shares of the biotechnology company's stock, valued at approximately $275,000.

Several other hedge funds and other institutional investors have also made changes to their positions in AXON. Fourth Dimension Wealth LLC bought a new position in Axon Enterprise during the 4th quarter worth about $30,000. Bartlett & CO. Wealth Management LLC grew its position in shares of Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after buying an additional 33 shares during the last quarter. Catalyst Capital Advisors LLC purchased a new position in shares of Axon Enterprise in the 1st quarter worth approximately $32,000. Alpine Bank Wealth Management purchased a new position in shares of Axon Enterprise in the 1st quarter worth approximately $40,000. Finally, Elequin Capital LP purchased a new position in shares of Axon Enterprise in the 4th quarter worth approximately $46,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Insider Buying and Selling

In related news, Director Michael Garnreiter sold 5,913 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00. Following the completion of the sale, the director owned 17,740 shares of the company's stock, valued at approximately $13,482,400. The trade was a 25.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Jennifer H. Mak sold 75 shares of the business's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $771.81, for a total transaction of $57,885.75. Following the completion of the sale, the chief accounting officer directly owned 15,240 shares of the company's stock, valued at approximately $11,762,384.40. The trade was a 0.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 44,642 shares of company stock worth $30,500,428 in the last 90 days. 4.40% of the stock is owned by insiders.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $729.62 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. The firm has a market cap of $56.80 billion, a price-to-earnings ratio of 176.24, a price-to-earnings-growth ratio of 84.37 and a beta of 1.29. The company has a 50 day moving average price of $752.67 and a 200-day moving average price of $640.95. Axon Enterprise, Inc has a 1-year low of $279.02 and a 1-year high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The business's quarterly revenue was up 31.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.15 EPS. Equities research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Barclays lifted their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Needham & Company LLC lifted their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Bank of America lifted their target price on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Wolfe Research assumed coverage on shares of Axon Enterprise in a research note on Monday. They issued an "outperform" rating for the company. Finally, The Goldman Sachs Group lifted their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.